- Home
- AMOD vs TENX Comparison
AMOD vs TENX Comparison
Compare AMOD & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMOD
- TENX
- Stock Information
- Founded
- AMOD 2014
- TENX 1967
- Country
- AMOD United States
- TENX United States
- Employees
- AMOD N/A
- TENX N/A
- Industry
- AMOD
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- AMOD
- TENX Health Care
- Exchange
- AMOD NYSE
- TENX Nasdaq
- Market Cap
- AMOD 16.5M
- TENX 21.7M
- IPO Year
- AMOD N/A
- TENX N/A
- Fundamental
- Price
- AMOD $1.36
- TENX $6.30
- Analyst Decision
- AMOD
- TENX Strong Buy
- Analyst Count
- AMOD 0
- TENX 3
- Target Price
- AMOD N/A
- TENX $16.00
- AVG Volume (30 Days)
- AMOD 181.5K
- TENX 20.7K
- Earning Date
- AMOD 05-15-2025
- TENX 05-13-2025
- Dividend Yield
- AMOD N/A
- TENX N/A
- EPS Growth
- AMOD N/A
- TENX N/A
- EPS
- AMOD N/A
- TENX N/A
- Revenue
- AMOD N/A
- TENX N/A
- Revenue This Year
- AMOD N/A
- TENX N/A
- Revenue Next Year
- AMOD N/A
- TENX N/A
- P/E Ratio
- AMOD N/A
- TENX N/A
- Revenue Growth
- AMOD N/A
- TENX N/A
- 52 Week Low
- AMOD $1.20
- TENX $2.77
- 52 Week High
- AMOD $13.49
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- AMOD N/A
- TENX 49.26
- Support Level
- AMOD N/A
- TENX $6.00
- Resistance Level
- AMOD N/A
- TENX $6.76
- Average True Range (ATR)
- AMOD 0.00
- TENX 0.40
- MACD
- AMOD 0.00
- TENX 0.02
- Stochastic Oscillator
- AMOD 0.00
- TENX 39.47
About AMOD ALPHA MODUS HOLDINGS INC
Alpha Modus Holdings Inc is a technology company with a core focus on artificial intelligence in retail. It is engaged in creating, developing and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.